...
首页> 外文期刊>Bone marrow transplantation >KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation.
【24h】

KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation.

机译:不相关的,12/12 HLA匹配的造血干细胞移植后,KIR基因和KIR配体会影响急性GVHD的发生。

获取原文
获取原文并翻译 | 示例
           

摘要

Interactions of polymorphic killer Ig-like receptor (KIR) receptors with KIR ligands have been shown to modify the outcome of hematopoietic SCT (HSCT). The association of these genetic factors with different transplantation endpoints, however, varies substantially, depending on clinical and study setup variables. We aimed to assess whether KIR ligands, KIR genes and KIR haplotypes are associated with HSCT outcome of 124 patients with various hematological malignancies, transplanted with 12/12 HLA matched grafts from unrelated donors. For this purpose, patient and donor KIR gene and KIR ligand polymorphisms were determined and correlated with clinical data in simple and multiple models. We found that a missing HLA-C2 ligand for donor inhibitory KIR2DL1 was significantly associated with an increased risk of acute GVHD (aGVHD) (II-IV) (hazard ratio (HR)=2.23, 95% confidence interval (95% CI): 1.21-4.10, P=0.010), as were the AA KIR haplotypes in patients and donors in HLA-C1CX (HR=2.37, 95% CI: 1.16-4.84, P=0.018) and in HLA-Bw4(-) (HR=3.20, 95% CI: 1.35-7.60, P=0.008) patients. On the contrary, transplantation of HLA-C1C2 patients with KIR2DS2 positive grafts were associated with a decreased risk of aGVHD (II-IV) (HR=0.24, 95% CI: 0.07-0.85, P=0.027). Thus, our single center study provides evidence for the modification of aGVHD risk by KIRs and their ligands.
机译:多态性杀伤性Ig样受体(KIR)受体与KIR配体的相互作用已显示可改变造血SCT(HSCT)的结果。但是,取决于临床和研究设置变量,这些遗传因素与不同移植终点之间的关联差异很大。我们旨在评估KIR配体,KIR基因和KIR单倍型是否与124例不同血液恶性肿瘤患者的HSCT结果相关联,这些患者移植了来自无关供体的12/12 HLA匹配移植物。为此,确定了患者和供体的KIR基因和KIR配体多态性,并将其与简单和多个模型中的临床数据相关联。我们发现缺少供体抑制性KIR2DL1的HLA-C2配体与急性GVHD(aGVHD)(II-IV)的风险增加显着相关(危险比(HR)= 2.23,95%置信区间(95%CI): 1.21-4.10,P = 0.010),以及HLA-C1CX(HR = 2.37,95%CI:1.16-4.84,P = 0.018)和HLA-Bw4(-)(HR)患者和供体的AA KIR单倍型= 3.20,95%CI:1.35-7.60,P = 0.008)患者。相反,用KIR2DS2阳性移植物移植HLA-C1C2患者与降低aGVHD(II-IV)的风险有关(HR = 0.24,95%CI:0.07-0.85,P = 0.027)。因此,我们的单中心研究为通过KIR及其配体改变aGVHD风险提供了证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号